POSNOC & ATNEC Trials Update by Amit Goyal: Investigating Axillary Treatment in Breast Cancer

 
Amit Goyal (Chief Investigator)
Consultant Oncoplastic Breast Surgeon & Associate Professor
Royal Derby Hospital, Derby, United Kingdom
 
POSNOC & ATNEC trials - update
POSNOC & ATNEC trials - update
 
 
 
POSNOC
POSNOC
PO
PO
sitive Sentinel 
sitive Sentinel 
NO
NO
de: adjuvant therapy alone versus
de: adjuvant therapy alone versus
adjuvant therapy plus 
adjuvant therapy plus 
C
C
learance or axillary radiotherapy
learance or axillary radiotherapy
 
A randomised controlled trial of axillary treatment in women with early stage
breast cancer who have metastases in one or two sentinel nodes
 
www.posnoc.co.uk
@POSNOC
 
POSNOC
POSNOC
 
3
 
Largest UK breast cancer surgical trial
Largest UK breast cancer surgical trial
1
1
st
st
 UK led international breast cancer surgical trial
 UK led international breast cancer surgical trial
 
 
Trial design
Breast or Chest wall RT, Systemic Therapy, Follow-up 5 years
Randomise (n=1900)
Patients with T1-2 invasive breast cancer undergoing
lumpectomy or mastectomy and sentinel node biopsy
Axillary recurrence, Arm morbidity, QoL, Survival
Systemic therapy alone
Systemic therapy plus axillary treatment
(axillary node clearance or axillary RT)
1 or 2 Sentinel Node Macrometastases
 
Inclusion Criteria
 
Women will be eligible for inclusion only if 
ALL 
of the following criteria
apply:
 
18 years or older
 
T1 or T2
 
Unifocal or multi-focal invasive tumour
 
1 or 2 nodes with macrometastases
 
Fit for axillary treatment and adjuvant therapy
 
Exclusion Criteria
 
Women will be excluded if they have:
Bilateral invasive breast cancer
more than 2 nodes with macrometastases
neoadjuvant therapy for breast cancer except
o
if sentinel node biopsy performed prior to neoadjuvant therapy in women with early breast cancer
o
short duration of neoadjuvant endocrine therapy is acceptable (up to 3 months)
Previous ipsilateral axillary surgery
not receiving adjuvant systemic therapy
previous cancer less than 5 years previously or concomitant malignancy
except
o
basal or squamous cell carcinoma of the skin
o
in situ carcinoma of the cervix
o
in situ melanoma
o
contra - or ipsilateral in situ breast cancer
 
P
O
S
N
O
C
 
v
s
.
 
Z
1
1
 
Reason for non-enrolment
Reason for non-enrolment
 
Recruitment
Recruitment
 
TOP 10
 
ATNEC
ATNEC
A
xillary management in 
T
1-3N1M0 breast cancer patients with needle
biopsy proven nodal metastases at presentation after 
ne
oadjuvant
c
hemotherapy
 
 
 
@ATNEC1
 
Largest UK neoadjuvant breast cancer surgical
Largest UK neoadjuvant breast cancer surgical
trial
trial
1
1
st
st
 UK led international neoadjuvant breast cancer
 UK led international neoadjuvant breast cancer
surgical trial
surgical trial
 
 
Research Question
 
T1-3N1M0 who convert to no residual cancer in the lymph glands (ypN0) after
NACT - 
omitting axillary treatment (removing all lymph glands in the armpit or
radiotherapy to the armpit), is non-inferior (no worse) than axillary treatment
T1-3,N1,M0 early stage breast cancer with needle biopsy (fine needle
aspiration or core biopsy) documented axillary node metastasis
NEOADJUVANT CHEMOTHERAPY (NACT)
Breast wide local excision or mastectomy + dual tracer
sentinel node biopsy (at least 3 nodes removed – sentinel
nodes + marked node)
Axillary ultrasound
No nodal metastasis
RANDOMISATION 1:1
Axillary treatment (n=950)
ALND or ART (as per local practice)
No Axillary
treatment (n=950)
Nodal metastasis
(ITCs, micro or macrometastases)
Standard axillary
treatment and follow-up
Mark the axillary node proven to have cancer cells on needle biopsy
(using clip 
or
 carbon  dye 
or
 seed – as per local practice)
 
ALND, axillary lymph node dissection
ART, axillary radiotherapy
Sample size – 1900, Follow up – 5 years
Co-primary outcomes – Disease free survival,
Lymphoedema
Eligible,
consent and
register
 
ATNEC trial
ATNEC trial
Axillary management in T1-3N1M0 breast
cancer patients with needle biopsy proven
nodal
metastases at presentation after
neoadjuvant chemotherapy
 
Study Design
 
Pragmatic randomised, multi-centre, international trial
 
Number of sites
  
100 (Target: 5 randomised per year/site)
 
Sample size = 1900
 
Timeline
o
Trial start date – 01 March 2020
 
 
Inclusion Criteria
 
Age ≥ 18
Male or female
T1-3N1M0 breast cancer at diagnosis (prior to NACT) by AJCC staging 7th
edition
FNA or core biopsy confirmed axillary nodal metastases at presentation
Oestrogen receptor, progesterone receptor and HER2 status evaluated on
primary tumour
Received standard NACT as per local guidelines
Ultrasound of the axilla at completion of NACT
Undergo dual tracer sentinel node biopsy after NACT and at least 3 nodes
removed (sentinel nodes and marked node)
No nodal metastases post NACT (isolated tumour cells, micro or
macrometastasis)
 
Exclusion Criteria
 
Bilateral invasive breast cancer
Sentinel node biopsy prior to NACT
Previous axillary surgery on the same body side as the
scheduled targeted sampling
Previous cancer within 5 years or concomitant malignancy
Stratification
Stratification
Institution
Type of breast surgery (wide local excision or mastectomy)
receptor status (triple negative, HER2+, ER/PR+ and HER2-)
 
Outcomes
 
Primary
o
Disease free survival
o
Lymphoedema (co-primary outcome)
Defined as ‘YES’ to arm swelling now and arm heaviness in past year (LBCQ
questionnaire)
 
Secondary
o
Arm morbidity and quality of life (QuickDASH, EQ5D5L)
o
local (breast or chest wall) and regional (nodal) recurrence
o
distant metastasis, axillary recurrence free interval, overall survival
o
contralateral breast cancer
o
non-breast malignancy
o
economic evaluation
 
 
Marking of node
 
Sites can adapt the pathways to their
local preference. *Subject to CE
marking. The node may be marked at
the time of needle biopsy or at a
separate visit.
 
Radiotherapy QA
 
 
National Radiotherapy Trials Quality
Assurance (RTTQA) Group
 Mount Vernon Cancer Centre | HA6 2RN
 
 
 
 
#makelymphoedemahistory
 
Contact: amit.goyal@nhs.net
 
Please sign up !!!
Slide Note
Embed
Share

POSNOC (Positive Sentinel Node) and ATNEC trials are investigating the effectiveness of axillary treatment in women with early-stage breast cancer having metastases in one or two sentinel nodes. Led by Chief Investigator Amit Goyal in the UK, this randomized controlled trial compares adjuvant therapy alone versus adjuvant therapy with axillary clearance or axillary radiotherapy. Patients with T1-2 invasive breast cancer undergo lumpectomy or mastectomy with sentinel node biopsy. Inclusion criteria include age over 18, unifocal or multifocal invasive tumor, and fit for axillary treatment and adjuvant therapy. Exclusion criteria cover various conditions like neoadjuvant therapy, previous axillary surgery, and recent malignancies. The trial aims to assess axillary recurrence, arm morbidity, quality of life, and survival over a 5-year follow-up period.


Uploaded on Jul 15, 2024 | 1 Views


Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

E N D

Presentation Transcript


  1. POSNOC & ATNEC trials - update Amit Goyal (Chief Investigator) Consultant Oncoplastic Breast Surgeon & Associate Professor Royal Derby Hospital, Derby, United Kingdom

  2. POSNOC POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes www.posnoc.co.uk @POSNOC

  3. POSNOC Largest UK breast cancer surgical trial 1st UK led international breast cancer surgical trial 3

  4. Trial design Patients with T1-2 invasive breast cancer undergoing lumpectomy or mastectomy and sentinel node biopsy 1 or 2 Sentinel Node Macrometastases Randomise (n=1900) Systemic therapy plus axillary treatment (axillary node clearance or axillary RT) Systemic therapy alone Breast or Chest wall RT, Systemic Therapy, Follow-up 5 years Axillary recurrence, Arm morbidity, QoL, Survival

  5. Inclusion Criteria Women will be eligible for inclusion only if ALL of the following criteria apply: 18 years or older T1 or T2 Unifocal or multi-focal invasive tumour 1 or 2 nodes with macrometastases Fit for axillary treatment and adjuvant therapy

  6. Exclusion Criteria Women will be excluded if they have: Bilateral invasive breast cancer more than 2 nodes with macrometastases neoadjuvant therapy for breast cancer except o if sentinel node biopsy performed prior to neoadjuvant therapy in women with early breast cancer o short duration of neoadjuvant endocrine therapy is acceptable (up to 3 months) Previous ipsilateral axillary surgery not receiving adjuvant systemic therapy previous cancer less than 5 years previously or concomitant malignancy except o basal or squamous cell carcinoma of the skin o in situ carcinoma of the cervix o in situ melanoma o contra - or ipsilateral in situ breast cancer

  7. POSNOC vs. Z11 Z11 POSNOC Size of metastases micrometastasis or macrometastasis macrometastasis Macrometastases 430 1700* Extranodal invasion x Mastectomy x Radiotherapy quality assurance x Mandatory pre-op axillary ultrasound x Sentinel node biopsy before NACT x *POSNOC recruitment ongoing (sample size 1900)

  8. Reason for non-enrolment

  9. Recruitment

  10. TOP 10 1 2 3 4 5 6 7 8 9 Royal Derby Hospital Wythenshawe Hospital Southmead Hospital Castle Hill Hospital John Radcliffe Hospital Belfast City Hospital Aberdeen Royal Infirmary Royal Melbourne Hospital Royal Marsden Hospital 93 39 38 36 35 34 34 34 33 10 The Royal Sussex County Hospital 31

  11. ATNEC Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy @ATNEC1

  12. Largest UK neoadjuvant breast cancer surgical trial 1st UK led international neoadjuvant breast cancer surgical trial

  13. Research Question T1-3N1M0 who convert to no residual cancer in the lymph glands (ypN0) after NACT - omitting axillary treatment (removing all lymph glands in the armpit or radiotherapy to the armpit), is non-inferior (no worse) than axillary treatment

  14. T1-3,N1,M0 early stage breast cancer with needle biopsy (fine needle aspiration or core biopsy) documented axillary node metastasis ATNEC trial Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy Mark the axillary node proven to have cancer cells on needle biopsy (using clip or carbon dye or seed as per local practice) NEOADJUVANT CHEMOTHERAPY (NACT) Axillary ultrasound Breast wide local excision or mastectomy + dual tracer sentinel node biopsy (at least 3 nodes removed sentinel nodes + marked node) Nodal metastasis (ITCs, micro or macrometastases) No nodal metastasis Eligible, consent and register Standard axillary treatment and follow-up RANDOMISATION 1:1 ALND, axillary lymph node dissection ART, axillary radiotherapy Sample size 1900, Follow up 5 years Co-primary outcomes Disease free survival, Lymphoedema Axillary treatment (n=950) ALND or ART (as per local practice) No Axillary treatment (n=950)

  15. Study Design Pragmatic randomised, multi-centre, international trial Number of sites 100 (Target: 5 randomised per year/site) Sample size = 1900 Timeline o Trial start date 01 March 2020

  16. Inclusion Criteria Age 18 Male or female T1-3N1M0 breast cancer at diagnosis (prior to NACT) by AJCC staging 7th edition FNA or core biopsy confirmed axillary nodal metastases at presentation Oestrogen receptor, progesterone receptor and HER2 status evaluated on primary tumour Received standard NACT as per local guidelines Ultrasound of the axilla at completion of NACT Undergo dual tracer sentinel node biopsy after NACT and at least 3 nodes removed (sentinel nodes and marked node) No nodal metastases post NACT (isolated tumour cells, micro or macrometastasis)

  17. Exclusion Criteria Bilateral invasive breast cancer Sentinel node biopsy prior to NACT Previous axillary surgery on the same body side as the scheduled targeted sampling Previous cancer within 5 years or concomitant malignancy Stratification Institution Type of breast surgery (wide local excision or mastectomy) receptor status (triple negative, HER2+, ER/PR+ and HER2-)

  18. Outcomes Primary o Disease free survival o Lymphoedema (co-primary outcome) Defined as YES to arm swelling now and arm heaviness in past year (LBCQ questionnaire) Secondary o Arm morbidity and quality of life (QuickDASH, EQ5D5L) o local (breast or chest wall) and regional (nodal) recurrence o distant metastasis, axillary recurrence free interval, overall survival o contralateral breast cancer o non-breast malignancy o economic evaluation

  19. Marking of node Sites can adapt the pathways to their local preference. *Subject to CE marking. The node may be marked at the time of needle biopsy or at a separate visit.

  20. Radiotherapy QA National Radiotherapy Trials Quality Assurance (RTTQA) Group Mount Vernon Cancer Centre | HA6 2RN

  21. #makelymphoedemahistory Contact: amit.goyal@nhs.net Please sign up !!! Yeovil District Hospital NHS Foundation Trust Poole Hospital NHS Foundation Trust Cheltenham General Hospital Royal United Hospitals Bath

Related


More Related Content

giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#